Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

Executive Summary

France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.


Related Content

Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate
Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline
Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie
Pipeline Watch: Phase III Starts With Tesetaxel, Molidustat, Imeglimin
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts